Prevest Denpro Ltd (PREVEST) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Prevest Denpro Ltd ₹415, price ₹377, upside +10.0%, quality 70 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Prevest Denpro Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
60‑month range ₹178.59 – ₹666.49 · fair‑value band ₹254.75 – ₹500.40 · the ₹377.05 price screens below the ₹414.76 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 3, 2026.
Follow Prevest Denpro in your weekly email
Every Wednesday you see whether Prevest Denpro is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Prevest Denpro Limited engages in the manufacture and distribution of dental materials and equipment in India and internationally.
Show more
Prevest Denpro Limited engages in the manufacture and distribution of dental materials and equipment in India and internationally. Its clinical products include adhesives, bonding agents, and etchants; composites; impression materials; retraction materials; auxiliaries; endodontics; temporary; cements and liners; finishing and polishing; orthodontics; and tooth whitening products. The company also provides laboratory products, such as acrylics, auxiliaries, base plates and waxes, and gypsum products. In addition, it offers oral care; 3D resins; and hygiene and disinfection products. Its products are used for endodontics, prosthodontics, periodontics, orthodontics, restorative dentistry, and aesthetic dentistry applications, as well as for the fabrication of prosthesis in dental laboratories. Prevest Denpro Limited was incorporated in 1999 and is based in Bari Brahmana, India.
Stock analysis
Prevest Denpro Ltd (PREVEST) currently trades at ₹377.05, while our model-based Fair Value estimate is ₹414.76, implying the stock looks roughly 9.1% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹411.35 per share, and 8 of the 26 models we run sit above the ₹377.05 price.
Bear case: the Asset-Based group reads lowest at ₹69.66, and 18 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: ₹254.75 (bear) to ₹500.40 (bull), the price of ₹377.05 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 70/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Prevest Denpro Ltd reported revenue of ₹718M in FY2026 versus ₹381M in FY2022, a compound +17.2%/yr. Reported net income was ₹205M in FY2026, compounding +15.4%/yr from FY2022.
Key figures
Market cap ₹4.5B (≈ $47.0M) · P/E ratio 20.8 · P/S ratio 5.94 · EPS (TTM) ₹18.10 · Dividend yield 0.3% · Net margin 28.5% · Return on equity 17.8% · Return on assets (EBIT) 67.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 31% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −37% fair-value upside, at 10%, PREVEST screens cheaper than that median.
Fair Value models
Bear ₹254.75Fair Value ₹414.76Bull ₹500.40
Price ₹377.05 · Upside +10.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹9.27 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+13.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.2%
Start year 2021 (pandemic)
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+17.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+16.9%
Dividend (yield on the price)0.3%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.31% → 32%
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+20.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +15.6% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 190 stocks
Beats the industry median on 8/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score70 · Top 25%
Fair Value upside+10.0% · Above median
Profitability
Return on equity (TTM)17.8% · Top 25%
Return on assets11.6% · Top 25%
Net margin (TTM)28.9% · Top 25%
Operating margin (TTM)32.7% · Top 25%
Growth and dividend
Revenue growth20.9% · Top 25%
Dividend yield (TTM)0.3% · Bottom 25%
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Prevest Denpro Ltd (PREVEST) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of ₹414.76 versus a price of ₹377.05, about +10% upside (undervalued).
What is the fair value of PREVEST?
Our model-based fair value for Prevest Denpro Ltd is ₹414.76 (as of Oct 3, 2026), built from audited fundamentals. The current price: ₹377.05.
What is the quality score of PREVEST?
Prevest Denpro Ltd has a Quality Score of 70/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Prevest Denpro Ltd (PREVEST)?
Our model-based price target is the fair value of ₹414.76 (as of Oct 3, 2026) from 26 valuation models. Cautious scenario ₹254.75, optimistic scenario ₹500.40. It is a calculation from audited fundamentals, not an analyst target.
What is the Prevest Denpro Ltd stock forecast for 2026?
Our models put fair value at ₹414.76, about +10% upside versus a price of ₹377.05 (undervalued). Cautious scenario ₹254.75, optimistic scenario ₹500.40. The calculation is refreshed regularly with new filings.
What is the revenue of Prevest Denpro Ltd (PREVEST)?
Prevest Denpro Ltd reported trailing-twelve-month revenue of about ₹751M (latest available figure, as of Oct 3, 2026).
Does Prevest Denpro Ltd pay a dividend?
Prevest Denpro Ltd currently shows a dividend yield of about 0.27% relative to its recent price (as of Oct 3, 2026).
What growth is priced into Prevest Denpro Ltd (PREVEST)?
For today's price to be fair in a discounted-cash-flow model, Prevest Denpro Ltd would have to grow free cash flow by +20.4 % per year for five years (discount rate 11.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +21.2 % per year. As of Oct 3, 2026.
What discount rate (WACC) does the fair value of PREVEST use?
Our models discount Prevest Denpro Ltd at 11.1 %: a base by market capitalisation (nano), damped by beta 0.59, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Prevest Denpro Ltd that is +20.4 % per year a year over ten years, using the same discount rate (11.1 %) and the same formula as our fair value.
How much growth has Prevest Denpro Ltd (PREVEST) delivered so far?
Over the past 5 years revenue at Prevest Denpro Ltd grew +21.2 % a year. The price currently implies +20.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Prevest Denpro Ltd (PREVEST) growing?
The median revenue growth in the sector is +4.8 % a year. That is the yardstick for the growth priced into Prevest Denpro Ltd (+20.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Prevest Denpro Ltd (PREVEST)?
The free-cash-flow yield on the price is 2.85 %: that much free cash flow Prevest Denpro Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Prevest Denpro Ltd (PREVEST)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Prevest Denpro Ltd it is ₹414.76 per share (as of Oct 3, 2026), against a price of ₹377.05. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Prevest Denpro Ltd stock overvalued or undervalued in 2026?
As of Oct 3, 2026, PREVEST trades below its calculated fair value: price ₹377.05, fair value ₹414.76, a gap of about +10% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PREVEST?
No. The price is what the market pays today (₹377.05); the fair value is what the company's own numbers justify (₹414.76). For Prevest Denpro Ltd the two are ₹37.71 per share apart. That gap is exactly why we show both numbers side by side.
How much is Prevest Denpro Ltd worth?
The market values Prevest Denpro Ltd at about ₹4.5B (market capitalisation, as of Oct 3, 2026). Per share that is ₹377.05; our models calculate a fair value of ₹414.76 per share.
What do the bullish and bearish scenarios say about PREVEST?
Our models span a range for Prevest Denpro Ltd: cautious scenario ₹254.75, base ₹414.76, optimistic ₹500.40 per share (as of Oct 3, 2026, price ₹377.05). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of PREVEST?
Prevest Denpro Ltd trades at a price-to-earnings ratio of 20.8 (as of Oct 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹414.76 is built from several models across several years. Other multiples: P/B 3.6, P/S 6.0, EV/EBITDA 14.5.
How solid is the balance sheet of Prevest Denpro Ltd (PREVEST)?
Balance-sheet figures for Prevest Denpro Ltd (as of Oct 3, 2026): return on equity 17.8%. They feed the Quality Score of 70/100, which measures business quality independently of the share price.
How far is PREVEST from its 52-week high?
Prevest Denpro Ltd trades at ₹377.05, about 31% below its 52-week high of ₹547.00 and 10% above the low of ₹341.80 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹414.76 is for.
Which stocks are comparable to Prevest Denpro Ltd?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Prevest Denpro Ltd stock attractive at the current price?
The data as of Oct 3, 2026: price ₹377.05, calculated fair value ₹414.76 (+10%), Quality Score 70/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PREVEST calculated?
We run Prevest Denpro Ltd through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹414.76, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Prevest Denpro Ltd currently trades 9 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Prevest Denpro Ltd (PREVEST)?
The closing price on Oct 1, 2026 was ₹377.05. Our model-based fair value is ₹414.76, about +10% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Prevest Denpro Ltd right now?
A fairly wide model range (₹254.75 to ₹500.40) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Key figures of Prevest Denpro Ltd
How large is the market capitalisation of Prevest Denpro Ltd (PREVEST)?
The market capitalisation of Prevest Denpro Ltd is ₹4.5B (≈ $47.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Prevest Denpro Ltd (PREVEST)?
The price-to-sales ratio of Prevest Denpro Ltd is 5.94 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Prevest Denpro Ltd (PREVEST)?
Earnings per share at Prevest Denpro Ltd are ₹18.10 (price ÷ EPS = P/E 20.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Prevest Denpro Ltd (PREVEST)?
The dividend yield of Prevest Denpro Ltd is 0.3% (payout 5.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Prevest Denpro Ltd (PREVEST)?
The net margin of Prevest Denpro Ltd is 28.5% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Prevest Denpro Ltd (PREVEST)?
The return on equity (ROE) of Prevest Denpro Ltd is 17.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Prevest Denpro Ltd (PREVEST)?
On an EBIT basis the return on assets of Prevest Denpro Ltd is 67.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Prevest Denpro Ltd (PREVEST)?
The operating margin of Prevest Denpro Ltd is 32.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Prevest Denpro Ltd (PREVEST)?
Revenue at Prevest Denpro Ltd is growing +20.9% versus a year earlier (3y avg +12.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Prevest Denpro Ltd (PREVEST)?
Earnings per share at Prevest Denpro Ltd are growing +28.1% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Prevest Denpro Ltd in the live analysis
One click puts Prevest Denpro Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
